

March 5, 2021

FOR IMMEDIATE RELEASE

Company name: H.U. Group Holdings, Inc.  
Representative: Shigekazu Takeuchi,  
Director, President and Group CEO  
Securities code: 4544 First Section, Tokyo Stock Exchange

## H.U. Group Begins Sale of Research Assay Reagents and Undertaking of Research Tests for Detecting IgM Antibodies of Novel Coronavirus

Fujirebio Inc. (President & CEO: Takeshi Fujita; Head Office: Shinjuku-ku, Tokyo; hereinafter "Fujirebio"), which is a consolidated subsidiary of H.U. Group Holdings, Inc., has commenced sale of a research assay reagent (hereinafter the "reagent") for IgM antibodies of novel coronavirus (SARS-CoV-2) as of March 5, 2021, under the product name of SARS-CoV-2 IgM (IB).

The reagent is a dedicated reagent for use with the LUMIPULSE® L2400 and LUMIPULSE® Presto II fully automated CLEIA (chemiluminescent enzyme immunoassay) instrument systems, also provided by Fujirebio.

SRL, Inc. (President & CEO: Shunichi Higashi; Head Office: Shinjuku-ku, Tokyo), also a consolidated subsidiary of H.U. Group Holdings, Inc., plans to start undertaking research tests using the reagent as of March 12, 2021.

Moving forward, the H.U. Group will continue working to develop reagents for novel coronavirus antibody tests.

End.

To inquire about this announcement, please use the contact information below

<For medical institutions>

Fujirebio Inc. Call Center

Phone: 0120-292-832 (toll-free in Japan only, weekdays 08:00–20:00)

For members of the media:

Public Relations Section, Corporate Communications Dept.

Phone: +81-3-6279-0884

e-mail: [pr@hugp.com](mailto:pr@hugp.com)

For investors and analysts:

IR/SR Section, Corporate Communications Dept.

Phone: +81-3-5909-3337

e-mail: [ir@hugp.com](mailto:ir@hugp.com)